Browsing by Author "Özden Ş."

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registry
    (Exon Publications, 2025) Beyaz Ş.; Erdinç M.; Hayme S.; Aslan A.F.; Aydın Ö.; Gökmen D.; Buhari G.K.; Sözener Z.Ç.; Gemicioğlu B.; Bulut İ.; Örçen C.; Özdemir S.K.; Keren M.; Damadoğlu E.; Yakut T.; Kalpaklıoğlu A.F.; Baccıoğlu A.; Yalım S.A.; Yılmaz İ.; Kalkan İ.K.; Uysal M.A.; Niksarlıoğlu E.Y.Ö.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayc S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Göksel Ö.; Karaoğlanoğlu S.; Erkekol F.Ö.; Isık S.R.; Yıldız F.; Yavuz Y.; Karadoğan D.; Bozkurt N.; Şeker Ü.; Oğuzülgen İ.K.; Başyiğit İ.; Barış S.A.; Uçar E.Y.; Erdoğan T.; Polatlı M.; Ediger D.; Günaydın F.E.; Türk M.; Pür L.; Katran Z.Y.; Sekibağ Y.; Aykaç E.F.; Mungan D.; Gül Ö.; Cengiz A.; Akkurt B.; Özden Ş.; Demir S.; Ünal D.; Can A.; Gümüşburun R.; Boğatekin G.; Akten H.S.; İnan S.; Öğüş A.C.; Kavas M.; Yuluğ D.P.; Çakmak M.E.; Kaya S.B.; Alpagat G.; Özgür E.S.; Uzun O.; Gülen Ş.T.; Pekbak G.; Kızılırmak D.; Havlucu Y.; Dönmez H.; Arslan B.; Çetin G.P.; Soyyiğit Ş.; Kara B.Y.; Karakış G.P.; Dursun A.B.; Kendirlinan R.; Öztürk A.B.; Sevinç C.; Şimşek G.Ö.; Abadoğlu Ö.; Çerçi P.; Yücel T.; Yorulmaz İ.; Tezcaner Z.Ç.; Tatar E.Ç.; Süslü A.E.; Özer S.; Dursun E.; Yorgancıoğlu A.; Çelik G.E.
    Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.76% (n = 1268; mean age: 46.2 ± 14.3 years), predominantly females (~76%), received montelukast. Montelukast users showed higher rates of allergic rhinitis (P < 0.001), hyper-sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) (P = 0.008), and chronic rhinosi-nusitis (P = 0.008). Montelukast group also had higher atopy and total IgE levels and tended to be more eosinophilic. Montelukast was commonly preferred in allergic, eosinophilic, NSAID-exacerbated respiratory disease, and severe asthma phenotypes (P < 0.001). Patients receiving Steps 4 and 5 treatments are more likely to be prescribed montelukast (P < 0.001). Montelukast usage was higher among patients with uncontrolled asthma [ACT< 20 (OR:1.29, 95%CI:1.052–1.582, P = 0.014)]. In addition, logistic regression analyses identified the main factors associated with increased montelukast use as; female gender (OR:1.33, 95%CI:1.041–1.713, P = 0.02), presence of atopy (OR:1.46, 95%CI:1.157–1.864, P = 0.002), comorbid allergic rhinitis (OR:2.12, 95%CI:1.679–2.293, P < 0.001), and severe asthma (OR:2.18, 95%CI:1.712–2.784, P < 0.001). These findings reveal that montelukast use is prevalent among asthma patients, particularly in females, middle-aged adults, and those with comorbid allergic rhinitis, uncontrolled asthma, or specific asthma phenotypes, underscoring the factors that influence its prescription in asthma management. © 2025 Codon Publications.